Electronic Supplementary Information

Applications of the class II lanthipeptide protease LicP for sequence-specific, traceless peptide bond cleavage

Weixin Tang,1,# Shi-Hui Dong,2,# Lindsay M. Repka,1 Chang He,1 Satish Nair,2,3* Wilfred A. van der Donk1*

1Department of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, 600 S. Mathews Ave., Urbana IL, 61801, USA.
2Department of Biochemistry, University of Illinois at Urbana-Champaign, 600 S. Mathews Ave., Urbana IL, 61801, USA.
3Center for Biophysics and Computational Biology, University of Illinois at Urbana-Champaign, 600 S. Mathews Ave., Urbana IL, 61801, USA.

Table of Contents

General methods .............................................................................................................. S1
Materials ................................................................................................................................ S2
Strains and plasmids ........................................................................................................... S2
Experimental methods ......................................................................................................... S2
Supplementary Tables ......................................................................................................... S13
Supplementary Figures ........................................................................................................ S20
References .......................................................................................................................... S43

General methods

All polymerase chain reactions (PCRs) were carried out on a C1000 thermal cycler (Bio-Rad). DNA sequencing was performed by ACGT, Inc. Preparative HPLC was performed using a Waters Delta 600 instrument equipped with a Waters Delta-pak C4 column (15 µm 300 Å 25 x 100 mm). Solid phase extraction was performed with a Strata-X polymeric reversed phase column (Phenomenex) or Vydac BioSelect C4 reversed phase column. FPLC was carried out using an AKTA FPLC system (Amersham Pharmacia Biosystems). MALDI-TOF MS was
carried out on a Bruker Daltonics UltrafleXtreme MALDI TOF/TOF instrument (Bruker). The detection of peptides with low molecular weights (700-3,500 Da), peptides with medium molecular weights (3,500-20,000 Da) and proteins with high molecular weights (20,000-50,000 Da) was achieved by using different instrument settings optimized for these mass ranges.

Materials
All oligonucleotides were synthesized by Integrated DNA Technologies and used as received. Restriction endonucleases, DNA polymerases, and T4 DNA ligase were obtained from New England Biolabs. Media components were purchased from Difco Laboratories and Fisher Scientific. Chemicals were ordered from Sigma Aldrich or Fisher Scientific unless otherwise specified. Miniprep, gel extraction and PCR purification kits were purchased from Qiagen and 5 PRIME. Synthetic genes were obtained from IDT, Inc. For LanP from Bacillus cereus VD156, the DNA was ordered in two gBlocks, whereas for the substrate it was ordered as one oligonucleotide. An UltraClean microbial DNA isolation kit was obtained from Mo Bio Laboratories, Inc.

Strains and plasmids
Bacillus licheniformis ATCC 14580 and Bacillus licheniformis ATCC 9945A were obtained from American Type Culture Collection. E. coli DH5α and E. coli BL21 (DE3) cells were used as hosts for cloning and plasmid propagation, and hosts for protein expression, respectively. The expression vector pRSFDuet-1 was obtained from Novagen.

Extraction of genomic DNA from B. licheniformis ATCC 14580 and B. licheniformis ATCC 9945A
Bacteria were cultured in LB medium at 37 °C aerobically for 12 h and the genomic DNA was extracted using an UltraClean microbial DNA isolation kit following the manufacturer’s protocol.

Construction of pRSFDuet-1 derivatives for expression of LicP-25-433 and LicA2
The genes licP and licA2 were amplified from genomic DNA of B. licheniformis ATCC 14580 using appropriate primers and cloned into the multiple cloning site 1 (MCS1) of a pRSFDuet-1 vector to generate pRSFDuet-1/LicP-25-433 and pRSFDuet-1/LicA2 plasmids, respectively. Primer sequences are listed in Table S2.
Construction of pRSFDuet-1 derivatives for expression of NDVNPE-ProcA1.7 and NDVNPE-NisA

Engineered peptide genes were generated by multi-step overlap extension PCR. First, the amplification of the 5’ leader part was carried out by 30 cycles of denaturing (95 °C for 10 s), annealing (55 °C for 30 s), and extending (72 °C for 15 s) using forward primers for procA1.7 and nisA and appropriate leader peptide reverse primers containing the mutations (Table S2) to generate a forward megaprimer (FMP). In parallel, PCR reactions using forward primers and reverse primers for procA1.7 and nisA core peptides (Table S2) were performed to produce the 3’ core fragments (termed reverse megaprimer, RMP). The 5’ FMP fragment and 3’ RMP fragment were purified by 2% agarose gel, combined in equimolar amounts and amplified using the same PCR conditions as above with procA1.7 and nisA primers. The resulting PCR products were purified, digested and then cloned into the MCS1 of a pRSFDuet-1 vector to generate pRSFDuet-1/NDVNPE-ProcA1.7 and pRSFDuet-1/NDVNPE-NisA plasmids.


Construction of pRSFDuet-1 derivatives for co-expression of LicM2 with LicA2
The licM2 gene was amplified from the genomic DNA of B. licheniformis ATCC 14580 using appropriate primers and cloned into the MCS2 of a pRSFDuet-1 vector to generate pRSFDuet-1/LicM2-2. The expression plasmid pRSFDuet-1/LicA2/LicM2-2 was constructed by inserting the licA2 gene into the MCS1 of the pRSFDuet-1/LicM2-2 plasmid. Primer sequences are listed in Table S2.

Construction of a pET28b-MBP-BamL plasmid containing the LicP recognition sequence
Oligonucleotides corresponding to the LicP recognition sequence NDVNPE/SGS were inserted into the pET28b-MBP-BamL plasmid1 in front of the DNA sequences corresponding to the TEV cleavage site using QuikChange methodology. Primer sequences are listed in Table S2.

Construction of pRSFDuet-1 derivatives for co-expression of LanM2-9945A with LanA2-9945A, and for expression of LanP-42-476-9945A
The genes for the LanM2 and LanA2 encoded in the genome of B. licheniformis ATCC 9945A (hereafter LanM2-9945A and LanA2-9945A, respectively) were amplified from the genomic DNA using appropriate primers and cloned into a pRSFDuet-1 vector to generate pRSFDuet-1/LanA2-9945A/LanM2-9945A-2 using Gibson assembly (LanA2 in MCS1 and LanM2 in MCS2). The gene encoding residues 42-476 of the class II LanP (designated LanP-42-476-9945A) was amplified from the genomic DNA of B. licheniformis ATCC 9945A using appropriate primers and cloned into the MCS1 of a pRSFDuet-1 vector to generate pRSFDuet-1/LanP-42-476-9945A using Gibson assembly. Primer sequences are listed in Table S2.

Construction of pRSFDuet-1 derivatives for expression of LanP and one LanA substrate encoded in the genome of B. cereus VD156
The lanP and lanA3 gene were synthesized as codon-optimized dsDNA oligos and cloned into a pRSFDuet-1 vector between BamHI and NotI restriction sites via Gibson Assembly. For expression in E. coli, the N-terminal secretion signal of the protease (the first 27 amino acids shown in red) was removed. The synthetic gene sequences are listed in Table S2.

Expression and purification of LicP and LicP mutant proteins
E. coli BL21 (DE3) cells were transformed with one of the following plasmids: pRSFDuet-1/LicP-25-433, pRSFDuet-1/LicP-25-433-S376A, pRSFDuet-1/LicP-25-433-H186A,
pRSFDuet-1/LicP-25-433-E100A or pRSFDuet-1/LicP-25-433-E100A-E102A, and plated on an LB plate containing 50 mg/L kanamycin. A single colony was picked and grown in 20 mL of LB containing 50 mg/L kanamycin at 37 °C for 12 h and the resulting culture was inoculated into 2 L of LB containing 50 mg/L kanamycin. Cells were cultured at 37 °C until the OD at 600 nm reached 0.5, cooled and IPTG was added to a final concentration of 0.1 mM. The cells were cultured at 18 °C for another 10 h before harvesting. The cell pellet was resuspended on ice in LanP buffer (20 mM HEPES, 1 M NaCl, pH 7.5 at 25 °C) and lysed by homogenization. The lysed sample was centrifuged at 23,700×g for 30 min and the pellet was discarded. The supernatant was passed through 0.45-µm syringe filters and the protein was purified by immobilized metal affinity chromatography (IMAC) loaded with nickel as previously described. The proteins were generally eluted from the column at an imidazole concentration between 150 mM and 300 mM and the buffer was exchanged using a GE PD-10 desalting column or a gel-filtration column pre-equilibrated with LanP buffer. Protein concentration was quantified by the absorbance at 280 nm. The extinction coefficient for His6-LicP-25-433 was calculated as 46,300 M⁻¹ cm⁻¹. His6-LicP-25-433-S376A was predominantly expressed in inclusion bodies. Soluble protein was obtained by combining fractions eluted from the nickel column containing the desired protein and concentrating to a small volume. Gel filtration chromatography was not performed for the mutant protein. The yield was determined to be about 50 µg for 1 L of culture. Aliquotted protein solutions were flash-frozen and kept at −80 °C until further usage.

Expression and purification of modified His6-LicA2

Modified LicA2 was obtained using a procedure similar to that reported previously using the corresponding co-expression plasmid pRSFDuet-1/LicA2/LicM2-23,4

Expression and purification of unmodified His6-LicA2, His6-G-LicA2, His6-NDVNPE-ProCA1.7, His6-NDVNPE-NisA, His6-NDVNPE-NisA-I1G, His6-NDVNPE-NisA-I1T, His6-NDVNPE-NisA-I1C, His6-NDVNPE-NisA-I1L, His6-NDVNPE-NisA-I1F, His6-NDVNPE-NisA-I1W, His6-NDVNPE-NisA-I1K, and His6-NDVNPE-NisA-I1E

E. coli BL21 (DE3) cells were transformed with one of the following plasmids: pRSFDuet-1/LicA2, pRSFDuet-1/G-LicA2, pRSFDuet-1/NDVNPE-ProCA1.7, pRSFDuet-1/NDVNPE-NisA, pRSFDuet-1/NDVNPE-NisA-I1T, pRSFDuet-1/NDVNPE-NisA-I1G, pRSFDuet-1/NDVNPE-NisA-I1C, and pRSFDuet-1/NDVNPE-NisA-I1E.
pRSFDuet-1/NDVNPE-NisA-I1L, pRSFDuet-1/NDVNPE-NisA-I1F, pRSFDuet-1/NDVNPE-NisA-I1W, pRSFDuet-1/NDVNPE-NisA-I1K or pRSFDuet-1/NDVNPE-NisA-I1E. Then the cells were plated on an LB plate containing 50 mg/L kanamycin. A single colony was picked and grown in 10 mL of LB containing 50 mg/L kanamycin at 37 °C for 12 h and the resulting culture was inoculated into 1 L of LB containing 50 mg/L kanamycin. Cells were cultured at 37 °C until the OD at 600 nm reached 0.5 and IPTG was added to a final concentration of 0.2 mM. The cells continued to be cultured at 37 °C for another 3 h before harvesting. The cell pellet was resuspended at room temperature in LanA start buffer (20 mM NaH2PO4, pH 7.5 at 25 °C, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol) and lysed by sonication. The sample was centrifuged at 23,700×g for 30 min and the supernatant was discarded. The pellet was then resuspended in LanA buffer 1 (6 M guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25 °C, 500 mM NaCl, 0.5 mM imidazole) and sonicated again. The insoluble portion was removed by centrifugation at 23,700×g for 30 min and the soluble portion was passed through 0.45-µm syringe filters. His-tagged peptides were purified by IMAC as previously described. The eluted fractions were desalted using reversed phase HPLC or a Strata X polymeric reversed phase SPE column. The desalted peptides were lyophilized and stored at −20 °C for future use.


E. coli BL21 (DE3) cells were transformed with one of the following plasmids: pRSFDuet-1/LicA2–E–1A, pRSFDuet-1/LicA2–E–1D, pRSFDuet-1/LicA2–E–1Q, pRSFDuet-1/LicA2–P–2A, pRSFDuet-1/LicA2–N–3A, pRSFDuet-1/LicA2–V–4A, pRSFDuet-1/LicA2–V–4L, pRSFDuet-1/LicA2–V–4N, pRSFDuet-1/LicA2–V–4F, pRSFDuet-1/LicA2–D–5A, pRSFDuet-1/LicA2–D–5K or pRSFDuet-1/LicA2–D–5V. The cells were then plated on an LB plate containing 50 mg/L kanamycin. A single colony was picked and grown in 7 or 20 mL of LB containing 50 mg/L kanamycin at 37 °C for 14.5–16.5 h and the resulting culture was used to inoculate 750 mL of LB containing 50 mg/L kanamycin. Cells were cultured at 37 °C until the OD at 600 nm reached 0.5–0.6 and IPTG was added to a final concentration of 0.2 mM. The cells continued to be cultured at 37 °C for another 3 h before harvesting. The cell pellet was resuspended in LanA start buffer and lysed by sonication. The sample was centrifuged at 15,377×g for 30 min and the supernatant was discarded. The pellet
was then resuspended in LanA buffer 1 and sonicated again. The insoluble portion was removed by centrifugation at 15,377×g for 30 min and the soluble portion was passed through 0.45-µm syringe filters. His-tagged peptides were purified by IMAC as previously described. Eluted fractions were desalted using a Vydac Bioselect C4 reversed phase SPE column. The desalted peptides were lyophilized, dissolved in water to a final concentration of 3 mg/mL and stored at −20 °C for future use.

**Intermolecular cleavage of His$_6$-LicP-25-433-S376A by His$_6$-LicP-25-433**
His$_6$-LicP-25-433-S376A and His$_6$-LicP-25-433 proteins were both diluted with LanP buffer to a final concentration of 0.2 mg/mL. Parallel reactions were set up for His$_6$-LicP-25-433 with a final protein concentration of 0.1 mg/mL in LanP buffer, His$_6$-LicP-25-433-S376A with a final protein concentration of 0.1 mg/mL in LanP buffer, and His$_6$-LicP-25-433-S376A and His$_6$-LicP-25-433 combined with a final protein concentration of 0.1 mg/mL each. The three reactions were allowed to proceed at room temperature for 0, 2, 4, 7 and 19 h before being stopped by addition of SDS loading buffer and boiling at 95 °C for 10 min and analyzed by SDS-PAGE.

**Removal of leader peptides of modified or linear LicA2**
Modified or linear LicA2 peptides were dissolved in H$_2$O to make a 3 mg/mL solution (340 µM). To a 17 µL solution of peptide (final peptide concentration 290 µM), 2 µL of 500 mM HEPES buffer (pH 7.5) was added followed by 1 µL of 1 mg/mL LicP (final protein concentration 1.1 µM). The reaction was incubated at room temperature for 6 h followed by MS analysis.

**Proteolytic cleavage of the leader peptides of engineered peptides**
NDVNPE-ProcA1.7 was dissolved in H$_2$O to a final concentration of 3 mg/mL (250 µM), whereas for NDVNPE-NisA and its mutant peptides, a 10 mg/mL peptide solution was made (1.3 mM). For NDVNPE-ProcA1.7, 15 µL of peptide solution (final peptide concentration 190 µM) was pre-mixed with 1 µL of 50 mM DTT and 2 µL of 500 mM HEPES buffer (pH 7.5), to which 2 µL of 0.1 mg/mL LicP (final protein concentration 210 nM) was added. The reaction was incubated at room temperature for 4 h before analysis. For NDVNPE-NisA-I1T and NDVNPE-NisA-I1C, 1 µL of peptide (final peptide concentration 65 µM) was pre-mixed with 1 µL of 50 mM DTT and 2 µL of 500 mM HEPES buffer (pH 7.5) in 14 µL H$_2$O, then 2 µL of 0.1 mg/mL LicP (final protein concentration 210 nM) was added. The reaction was incubated at room temperature for 20 h before analysis. For NDVNPE-NisA and other NisA mutant peptides,
1 mg/mL LicP (final protein concentration 2.1 µM) was employed instead of 0.1 mg/mL LicP and the reaction was kept at room temperature for 30 h before analysis.

**Sequential proteolytic cleavage of modified LicA2**
HPLC-purified LicM2-modified LicA2 was dissolved in H₂O to a final concentration of 3 mg/mL (340 µM). To a 17 µL solution of peptide (final peptide concentration 290 µM), 2 µL of 500 mM HEPES buffer (pH 7.5) was added followed by 1 µL of 0.5 mg/mL AspN. The reaction mixture was kept at room temperature for 12 h, and then 0.5 µL of 0.1 mg/mL LicP (final protein concentration 50 nM) was added. The reaction was then incubated at room temperature for one more hour. MALDI-TOF MS analysis was performed after each step.

**Assay of modified and linear LicA2 peptides treated independently with LicP using HPLC and SDS-PAGE**
Three *in vitro* assays were conducted to compare the time dependence of LicP activity toward modified and linear LicA2 peptides at one concentration using HPLC and SDS-PAGE analysis. The relative activity was further analyzed in a competition assay using MS analysis (see below). As discussed in the main text, Michaelis-Menten kinetic experiments were not possible due to poor solubility of the peptides. Although 3 mg/mL stock solutions of modified and linear LicA2 could be prepared, these solutions were made from HPLC-purified peptides and therefore contain residual TFA. LicA2 is soluble at lower pH but upon incubation under physiological conditions (pH 7.5), both modified and linear LicA2 precipitate. Therefore, the following in vitro assays were heterogeneous due to poor solubility of the peptides.

1) Linear wild type LicA2 (100 µM) was incubated with 0.4 µM His₆-LicP-25-433 and 2 mM DTT in 50 mM HEPES (pH 7.5) buffer at room temperature with a total reaction volume of 75 µL. After 5 min, 15 min, 30 min and 2 h, the reaction was centrifuged for 30 s to 1 min at 2000×g and a 13.6 µL aliquot was removed and quenched by addition of 3.5 µL 5% aqueous formic acid to give a final concentration of 1%.

2) Modified wild type LicA2 (100 µM) was incubated with 0.4 µM His₆-LicP-25-433 and 2 mM DTT in 50 mM HEPES (pH 7.5) buffer at room temperature with a total reaction volume of 50 µL. After 5 min, 15 min and 30 min, quenched aliquots were prepared as described above.

3) Modified wild type LicA2 (100 µM) was incubated with 0.1 µM His₆-LicP-25-433 and 2 mM DTT in 50 mM HEPES (pH 7.5) buffer at room temperature with a total reaction volume of 64 µL. After 5 min, 15 min, 30 min and 2h, quenched aliquots were prepared as described above.
Samples for HPLC analysis were prepared as follows: 7.5 μL of each formic-acid quenched sample from the linear LicA2 assay was combined with 12.5 μL of 32 mM TCEP followed by incubation at room temperature for at least 3 h in order to fully reduce disulfides. To 7.5 μL of each formic-acid quenched sample from assays involving modified LicA2 was added 12.5 μL H2O. Aliquots of 30 μM modified LicA2 and 30 μM linear LicA2, which was incubated in 20 mM TCEP at room temperature for 3 h, were used as precursor peptide standards. HPLC was conducted using an Agilent 1260 Liquid Chromatography (HPLC) system (Agilent Technologies) and absorbance was monitored at 220 nm. The samples (5 μL) were injected on a C18 Mass Spec Vydac column (#218MS5120). A linear gradient of 2:98 to 100:0 B:A over 45 min (B = 80% MeCN/20% H2O/0.086% TFA; A = 0.1% aqueous TFA) was used with a flow rate of 0.1 mL/min, giving a retention time of 34.1 min for leader peptide and retention times of 37.5 min and 41.4 min for linear and modified LicA2 precursor peptides, respectively. The identity of peaks in the HPLC traces was confirmed by MALDI-TOF MS analysis.

Samples for SDS-PAGE analysis were prepared as follows. To 4.5 μL of each formic-acid quenched sample was added 1.5 μL of 95:5 4X NuPAGE LDS sample buffer:β-mercaptoethanol. Standard samples of 60 μM linear and modified LicA2 were prepared from 1.5 μL of 3 mg/mL peptide (336 and 344 μM), 4.8 μL H2O and 2.1 μL 95:5 4X NuPAGE LDS sample buffer:β-mercaptoethanol. The Polypeptide Standards (#161-0326) sample was prepared from 20 μL of 20-fold diluted 161-0326, 10 μL H2O and 10 μL 95:5 4X NuPAGE LDS sample buffer:β-mercaptoethanol. All SDS-PAGE samples were heated for 10 min at 70 ºC and then loaded on a 10-20% Mini-Protean Tris-Tricine gel (#456-3116) adding 5 μL per lane. The gel was run at 100 V for 125 min in 100 mM Tris, 100 mM Tricine, and 0.1% SDS buffer while cooling the entire apparatus in ice. The gel was then subjected to consecutive coomassie and silver staining as described below. The gels were rocked for 1 h in 50% MeOH/7% AcOH followed by rocking for 45 min in coomassie stain (0.25% coomassie/50% MeOH/10% AcOH), rinsing with H2O, rocking overnight in 20% MeOH/10% AcOH, and then rinsing with H2O again. All of the following steps were conducted with agitation on a Barnstead LabLine multipurpose rotator. The gels were washed with 50% MeOH/7% AcOH for 1.5 h, followed by washing with H2O (3 x 10 min). The gels were then sensitized 1 min in 0.02% Na2S2O3, then washed with H2O (2 x 1 min), followed by staining for 30 min in a solution containing 44 mL of H2O, 5.9 mL of 0.1 M AgNO3, and 37.5 μL of 37% formaldehyde. The gels were then washed with H2O (< 1 min) and developed for < 5 min in a solution containing 100 mL of 3% Na2CO3, 2 mL of 0.02% Na2S2O3, and 50 μL of 37% formaldehyde. Developing was quenched by washing with 12%
AcOH for 30 min, followed by washing with H$_2$O (2 x 30 min). Images of gels were acquired using an HP scanjet 8250.

**Competition assay of LicP activity with modified and linear LicA2**

To a reaction vessel containing 70 μL deionized H$_2$O, 5 μL each of 3 mg/mL modified LicA2 and linear G-LicA2 peptides were added (final peptide concentration 17 μM each) followed by 10 μL of 500 mM HEPES buffer (pH 7.5). Then, 10 μL of 0.01 mg/mL LicP was supplied (final protein concentration 21 nM) and the reaction was incubated at room temperature before being quenched by addition of formic acid to a final concentration of 1% at different time points. To observe the complete consumption of both peptides, substrates were incubated as above except that 10 μL of 1 mg/mL LicP was added (final protein concentration 2.1 μM). The reaction mixture was kept at room temperature for 12 h before being quenched with 1% formic acid for MS analysis.

**Comparison of the proteolytic activity of LicP and TEV on MBP-BamL**

A sample of 1 mL of MBP-BamL (50 μM) was incubated with the same molar amount of LicP or TEV (final concentration 0.54 μM) at 4 °C. At different time points, the reaction was quenched by adding an equal volume of loading dye and heating for 10 min at 90 °C. The results were analyzed by Coomassie-stained SDS-PAGE. The size difference between the product bands is a consequence of slightly different recognition site locations in the construct.

**LicP assay and SDS-PAGE analysis for wild type linear His$_6$-LicA2 and linear His$_6$-LicA2 mutants**

Linear LicA2 peptides (100 μM) were incubated with 0.4 μM His$_6$-LicP-25-433 and 2 mM DTT in 50 mM HEPES buffer (pH 7.5) at room temperature with a total reaction volume of 300 μL. The reactions were heterogeneous as a consequence of the poor solubility of the peptides. After 15 min, 30 min, 1 h, 2 h, 4 h and 7.5 h, the reactions were centrifuged for 30 s at 2000xg and 40 μL aliquots were removed and quenched by addition of 10.4 μL 5% aqueous formic acid to give a final concentration of 1%.

Samples for SDS-PAGE analysis were prepared as follows. To 5.1 μL of each formic-acid quenched sample was added 1.7 μL of 95:5 4X NuPAGE LDS sample buffer:β-mercaptoethanol. Standard samples of 60 μM LicA2 substrates were prepared from 1.5 μL of 3 mg/mL peptide (334 – 338 μM), 4.8 μL H$_2$O and 2.1 μL 95:5 4X NuPAGE LDS sample

S10 / 43
Identification of the cleavage sites of the LanP proteases encoded in the genomes of B. licheniformis 9945A and B. cereus VD156

The LanP proteases from B. licheniformis 9945A and B. cereus VD156 were purified using a procedure similar to that described for LicP. A His$_6$-tagged version of dehydrated and cyclized LanA2 encoded in the genome of B. licheniformis 9945A was obtained by co-expression of the precursor peptide with its corresponding LanM synthetase in E. coli using the same procedure as described for LicA2/LicM2. Linear LanA3 encoded in the genome of B. cereus VD156 was also obtained by expression in E. coli as an N-terminal His$_6$-tagged peptide. After IMAC and HPLC purification, the peptides were incubated with their corresponding purified proteases and the results were analyzed using MALDI-TOF MS.

Purification and crystallization of LicP

Purification of LicP for crystallization employed a slightly modified procedure from that described above. Briefly, E. coli cells containing overexpressed LicP were lysed by sonication and the lysates were clarified by centrifugation at 4 °C. The clear supernatant containing the soluble fraction was loaded onto a 5 mL immobilized metal ion affinity resin column (Hi-Trap Ni-NTA, G.E. Healthcare) pre-equilibrated with binding buffer (1 M NaCl, 5% glycerol, 20 mM Tris, pH 8.0, 4 °C). The column was washed with 50 mL of 88:12 (v:v) binding buffer: elution buffer (1 M NaCl, 250 mM imidazole, 20 mM Tris, pH 8.0), and the protein was eluted by a linear gradient to 100% elution buffer. Coomassie-stained SDS-PAGE was used to analyze fractions for purity and the cleanest fractions were combined. Samples were further fractionated using anion exchange chromatography (Hi-Trap Q HP, GE Healthcare), and appropriate fractions were combined and adjusted to pH 8.0 using HCl (LicP eluted at ~400 mM NaCl, 20 mM Tris, pH 8.9, 4 °C). The protein was concentrated using Amicon Ultra-4 centrifugal filters (10 kDa molecular weight cut-off, Millipore) and stored in liquid nitrogen until needed. Some aliquots of protein solution were further purified by size exclusion chromatography (Superdex HiLoad 75
16/60, GE Healthcare) in 300 mM KCl, 20 mM HEPES, pH 7.5 buffer. The final concentration of purified protein was quantified by Bradford analysis (Thermo Scientific).

Protein from both anion exchange and size exclusion purifications was used for crystallization by the hanging drop vapor diffusion. Samples purified by anion exchange afforded crystals using a precipitant solution containing 0.05 M cadmium sulfate, 0.1 M HEPES, pH 7.5, 1 M sodium acetate and 8% formamide added to a LicP solution (8.9 mg/mL) in a 1:1 ratio (v/v). Protein purified using size exclusion chromatography afforded crystals when mixed with a solution containing 0.2 M di-ammonium hydrogen citrate, 20% w/v PEG 3350, 2% tacsimate pH 7.0, and 4 mM HEPES pH 6.8. Crystals were stepwise equilibrated with incremental concentrations of glycerol or PEG 3350 up to a final concentration of 30% prior to vitrification by direct immersion in liquid nitrogen.

All diffraction data were collected at insertion device synchrotron beam lines (LS-CAT Sector 21 ID, Advanced Photon Source, Argonne, IL). All data were indexed and scaled using either the HKL20005 or XDS package6. Crystallographic phases were determined by the molecular replacement method as implemented in Phaser7 using the coordinates of the S8 peptidase from S. aureus determined by the Center for Structural Genomics of Infectious Diseases (PDB Code = 3QFH; 40% sequence identity). There are 8 copies of LicP in the crystallographic assymmetric unit and non-crystallographic symmetry averaging yielded maps of exceptional quality, allowing nearly the entire polypeptide chain to be manually fitted and adjusted using COOT.8 Cross-validation, using 5% of the data for the calculation of the free R factor,9 was utilized throughout model building process in order to monitor building bias. The stereochemistry of all of the models was routinely monitored throughout the course of refinement using PROCHECK.10 Relevant data collection and refinement parameters are provided in Table S1. The coordinates for the LicP structure can be accessed under code 4ZOQ in the Protein Data Bank.
Table S1. Data collection, phasing and refinement statistics.

<table>
<thead>
<tr>
<th></th>
<th>Native 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data collection</strong></td>
<td></td>
</tr>
<tr>
<td>a, b, c (Å)</td>
<td>71.0, 112.8, 114.8</td>
</tr>
<tr>
<td>α, β, γ (°)</td>
<td>82.2, 89.7, 82.9</td>
</tr>
<tr>
<td>Resolution (Å)¹</td>
<td>50.00 - 2.35</td>
</tr>
<tr>
<td></td>
<td>(2.45 - 2.35)</td>
</tr>
<tr>
<td>Total reflections</td>
<td>568,612</td>
</tr>
<tr>
<td>Unique reflections</td>
<td>143,709</td>
</tr>
<tr>
<td>R_{sym} (%)</td>
<td>8.6 (88.5)</td>
</tr>
<tr>
<td>I/σ(I)</td>
<td>13.14 (1.73)</td>
</tr>
<tr>
<td>Completeness (%)</td>
<td>98.5 (97.8)</td>
</tr>
<tr>
<td>Redundancy</td>
<td>4.0 (4.0)</td>
</tr>
</tbody>
</table>

| **Refinement**      |                            |
| Resolution (Å)      | 25.0 – 2.35                |
| No. reflections used| 143,685                    |
| R_{work} /R_{free}³ | 19.9/24.9                  |

| **Number of atoms** |                           |
| Protein             | 24,462                     |
| Solvent             | 1,100                      |

| **B-factors**       |                           |
| Protein             | 51.8                       |
| Peptide             | 49.4                       |

| **R.m.s deviations**|                           |
| Bond lengths (Å)    | 0.011                      |
| Bond angles (°)     | 1.54                       |

1. Highest resolution shell is shown in parenthesis.
2. Figure of merit- Probability weighted average of the cosine of the phase error, before and after density modification.
3. R-factor = \( \frac{\sum |F_{\text{obs}}|-k|F_{\text{calc}}|}{\sum |F_{\text{obs}}|} \) and R-free is the R value for a test set of reflections consisting of a random 5% of the diffraction data not used in refinement.

<table>
<thead>
<tr>
<th>Primer Name</th>
<th>Primer Sequence (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>LicP_25_BamHI_FP</td>
<td>AAAAA GGATCCG AAAGAACAAGCAGGAGAAGAAG</td>
</tr>
<tr>
<td>LicP_NotI_RP</td>
<td>AAAAA GCGGCCGC TCACCTCTTGG TTTATCATTTT G</td>
</tr>
<tr>
<td>LicA2_BamHI_FP</td>
<td>AAAAA GGATCCG ATGAAAACAA TGAAAAATTC TG</td>
</tr>
<tr>
<td>LicA2_NotI_RP</td>
<td>AAAAA GCGGCCGC ATGAAAACAA TGAAAAATTC TG</td>
</tr>
<tr>
<td>LicM2_Ndel_FP</td>
<td>AAAAA CATATG TTTTTCT TGCAGGCAGT G</td>
</tr>
<tr>
<td>LicM2_KpnI_RP</td>
<td>AAAAA GATACGG ATGAAAACAA TGAAAAATTC TG</td>
</tr>
<tr>
<td>G-LicA2__QC_FP</td>
<td>CCAGGAT GGT ATGAAAAAC AATGAAA AATTCAGCGTCCCGT</td>
</tr>
<tr>
<td>G-LicA2 QC_RP</td>
<td>GTTTTTCAT ACC ATGTTG GCT GGTGATGA CGT GGTGATG</td>
</tr>
<tr>
<td>ProcA1.7_EcoRI_FP</td>
<td>GGT GCG AGG AAT TCG ATG AAG CAT AGA CAA CTA AAT CTG</td>
</tr>
<tr>
<td>ProcA1.7_NotI_RP</td>
<td>ATA ATA TCG CCG CCG CTC AGC ACA TTT TCC C</td>
</tr>
<tr>
<td>NisA_BamHI_FP</td>
<td>CTA GAT GGA TCC GAT GAG TAC AAA AGA TTT TAA CTT GG</td>
</tr>
<tr>
<td>NisA_HindIII_RP</td>
<td>CTA GAA GCT TTT ATT TGC TTA GCT GAA TAC TAC AAT G</td>
</tr>
<tr>
<td>LicP-S376A QC_FP</td>
<td>GGAACA GCA TTGGCC GCCTGGC CAGGTAGCT</td>
</tr>
<tr>
<td>LicP-S376A QC_RP</td>
<td>GG CCAA TGC TGT TCC GTATGAG AGGGAATATC CTCCTTGGGT</td>
</tr>
<tr>
<td>LicP-H186A QC_FP</td>
<td>ACA GGA GCC GGAAC ACA ACGCCGGGATGATCAATATC</td>
</tr>
<tr>
<td>LicP-H186A QC_RP</td>
<td>GTCC GGC TCC TGT CGGATCT CGGATACGC CTCCTTGGGT</td>
</tr>
<tr>
<td>LicP-E100A QC_FP</td>
<td>CAGTAAAC GCA ACGGAATC A GTCATCAGCGGTTCGCC</td>
</tr>
<tr>
<td>LicP-E100A QC_RP</td>
<td>GATTCGGTTGCGTCTACTG CTGTTATT TGCAATCGGC</td>
</tr>
<tr>
<td>LicP-E100A E102A QC_FP</td>
<td>GCAACG GCA TCAGTC ATCAGCGGTTCGCT</td>
</tr>
<tr>
<td>LicP-E100A E102A QC_RP</td>
<td>GACTGA TGC CGTGGC GTTTTA CGTCTGGTTATT TGCAATCGGC</td>
</tr>
<tr>
<td>ProcA1.7 core_FP</td>
<td>ACCATTGGGGGA ACCATTGGT</td>
</tr>
<tr>
<td>ProcA1.7 NDVNPE _RP</td>
<td>GGT GCC CCAATGGT TTCAGGATTGACGTCATT CAG</td>
</tr>
<tr>
<td>NisA core _FP</td>
<td>ATTACAAGTATTTTCGCTATGT</td>
</tr>
<tr>
<td>NisA-NDVNPE _RP</td>
<td>CGAAATCTTT GTAAT TTAGGAGTACGCTATT ATCTTTC</td>
</tr>
</tbody>
</table>

S14 / 43
TTCGAAACAG ATA

NDVNPE-NisA-I1G_QC_FP CAATCCTGAA GGT ACAAGTATTTG GCTATGTACACC CGGTGTAAAAC

NDVNPE-NisA-I1G_QC_RP GAAATACCTTTG ACC TTCAGGATTG ACGTCATATCTTTTCTCAGAACAATACACC

NDVNPE-NisA-I1C_QC_FP CAATCCTGAA TGT ACAAGTATTTT GCTATGTACACC CGGTGTAAAAC

NDVNPE-NisA-I1C_QC_RP GAAAT ACGCTTGT ACA TTCAGGATTG ACGTCATATCTTTTCTCAGAACAATACACC

NDVNPE-NisA-I1T_QC_FP CAATCCTGAA ACC ACAAGTATTTT GCTATGTACACC CGGTGTAAAAC AG

NDVNPE-NisA-I1T_QC_RP GAAAT ACTTTGT GGT TTCAGGATTG ACGTCATATCTTTTCTCAGAACAATACACC

NDVNPE-NisA-I1L_QC_FP CAATCCTGAA CTT ACAAGTATTTT GCTATGTACACC CGGTGTAAAAC

NDVNPE-NisA-I1L_QC_RP GAAATACTTGT AAG TTCAGGATTG ACGTCATATCTTTTCTCAGAACAATACACC

NDVNPE-NisA-I1F_QC_FP CAATCCTGAA TTT ACAAGTATTTT GCTATGTACACC CGGTGTAAAAC

NDVNPE-NisA-I1F_QC_RP GAAATACTTTGT AAA TTCAGGATTG ACGTCATATCTTTTCTCAGAACAATACACC

NDVNPE-NisA-I1W_QC_FP CAATCCTGAA TGG ACAAGTATTTT GCTATGTACACC CGGTGTAAAAC

NDVNPE-NisA-I1W_QC_RP GAAATACTTGT CCA TTCAGGATTG ACGTCATATCTTTTCTCAGAACAATACACC

NDVNPE-NisA-I1K_QC_FP CAATCCTGAA AAA ACAAGTATTTT GCTATGTACACC CGGTGTAAAAC

NDVNPE-NisA-I1K_QC_RP GAAATACTTTGT CTT TTCAGGATTG ACGTCATATCTTTTCTCAGAACAATACACC

NDVNPE-NisA-I1E_QC_FP CAATCCTGAA GAA ACAAGTATTTT GCTATGTACACC CGGTGTAAAAC

NDVNPE-NisA-I1E_QC_RP GAAATACTTGT TTT TTCAGGATTG ACGTCATATCTTTTCTCAGAACAATACACC

MBP-BamL-NDVNPE_QC_FP AATGACGTCAATCCTGAA TCTGGTTCT
GAGAAACCTGTACTTCAAATCC

MBP-BamL-NDVNPE_QC_RP
LicA2-E–1A_QC_FP
LicA2-E–1A_QC_RP
LicA2-E–1D_QC_FP
LicA2-E–1D_QC_RP
LicA2-E–1Q_QC_FP
LicA2-E–1Q_QC_RP
LicA2-P–2A_QC_FP
LicA2-P–2A_QC_RP
LicA2-N–3A_QC_FP
LicA2-N–3A_QC_RP
LicA2-V–4A_QC_FP
LicA2-V–4A_QC_RP
LicA2-V–4L_QC_FP
LicA2-V–4L_QC_RP
LicA2-V–4N_QC_FP
LicA2-V–4N_QC_RP
LicA2-V–4F_QC_FP
LicA2-V–4F_QC_RP
LicA2-D–5A_QC_FP
LicA2-D–5A_QC_RP
LicA2-D–5K_QC_FP
LicA2-D–5K_QC_RP
LicA2-D–5V_QC_FP
LicA2-D–5V_QC_RP
9945M2-Gib-FseI-FP
9945M2-Gib-KpnI-RP
9945A2-Gib-BamHI-FP

TTTACCAGA CTCGGAGGTA CC TTAACATACG GCTCCTCCCT T
ACCA TCTACACCAC AGCCAG GATCCG

GACGTC GCT CCTGAA ACAACTCTGCTACAACCTCT

GAGTTTG TG AGGATTGACGTCATTAGATCCACCG GAACCAG

TTCAATCCT GCA ACAACTC CTGCTACAACCTCTTTTTGG AC
GAGTTGT TGC AGGA TTGA CGTCAATCTCCTACCAA GC
GAGTTGT TTG AGGATTGACGTCATTAGATCCACCG GAACCAG
ACGTCAAT GCT GAA ACA CTCTGCTACAACCTCTTTTG
TTGTT TC AGC ATTGA CGT CATTTCC TCCTACCAAA GC
GAGTTGT TTG AGGATTGACGTCATTAGATCCACCG GAACCAG
TCAGGATT CAG GTCAATCTCCTACAACCTCT
GAAATGAC CTG AATCTCCTGCTACAACCC TCTT
GAAATGAC ACAATCTCCTGCTACAACCTCTT
CAGATTGTCGTATTTCTCCTACAAAGCCTTCAAATTCC
GAAATGAC CTG AATCTCCTGCTACAACCC TCTT
GAAATGAC ACAATCTCCTGCTACAACCTCTT
GAAATGAC ACAATCTCCTGCTACAACCTCTT
GAAATGAC ACAATCTCCTGCTACAACCTCTT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
GAGTTGAC GGC ATTTCC TCCTACCAA GCTTTCAAATT CCTCT
<table>
<thead>
<tr>
<th>Sample</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>9945A2-Gib-HindIII-RP</td>
<td>TTAAGCAT TATGCGGCG CA AGCTT TTAGCAATCA</td>
</tr>
<tr>
<td></td>
<td>GATGTACATG C</td>
</tr>
<tr>
<td>9945LanP42-Gib-BamHI-FP</td>
<td>TTAAGCAT TATGCGGCG CA AGCTT TTAGCAATCA</td>
</tr>
<tr>
<td></td>
<td>GATGTACATG C</td>
</tr>
<tr>
<td>9945LanP42-Gib-BamHI-FP</td>
<td>TTAAGCAT TATGCGGCG CA AGCTT TTAGCAATCA</td>
</tr>
<tr>
<td></td>
<td>GATGTACATG C</td>
</tr>
</tbody>
</table>
Table S3. Sequences of the synthetic genes for the protease from *B. cereus* VD156 optimized for expression in *E. coli*. The sequence shown in red is predicted to be a secretion signal and was removed in the expression constructs. Also shown is the sequence of the LanA3 precursor peptide. The observed cleavage occurred after the Arg shown in blue (Fig. S20).

<table>
<thead>
<tr>
<th>Name</th>
<th>Accession number</th>
<th>Sequence (The predicted protease cleavage site is indicated in blue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strain: <em>B. cereus</em> VD156</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LanA3</td>
<td>EJR72967.1</td>
<td>MKNIKSESVGLSMKKLDTTEMEKYYGAGVDTRTHPTVVVSRAS5SKFCVTAASALLSYMNK</td>
</tr>
<tr>
<td></td>
<td>optimized</td>
<td>ATGAAAAATA TTTCAAGAAG ATCAGTACG GTTACAGTGA AGAAGCTGCA TACCACGGA</td>
</tr>
<tr>
<td></td>
<td>nucleotide</td>
<td>ATGGAAGAA TCTATGGGCG GTCTGGTGT ACGACGCGTA CGCATCCCAC AGTACGTCGA</td>
</tr>
<tr>
<td></td>
<td>sequence</td>
<td>GTGAGCCGCG CCAAGTCAAA ATTTTGGGTC ACCGTACGCT CCTCTGAC TATCAGTAT</td>
</tr>
<tr>
<td></td>
<td>optimized</td>
<td>AATACGTAATA AGTTAAAAAGT</td>
</tr>
<tr>
<td>LanP</td>
<td>EJR72593.1</td>
<td>MYRFKYYSLISFILISSFPNNTNAATQIAYSLIDSNDTDFNTVLKLDKNDQVYVVSPEVNLIQVKG</td>
</tr>
<tr>
<td></td>
<td>optimized</td>
<td>ATGGAAAAA TCTATGGCGC GTCTGGTGTA GACACGCGTA CGCATCCCAC AGTACGTCGA</td>
</tr>
<tr>
<td></td>
<td>nucleotide</td>
<td>GTGAGCCGAG TTAAGTACG GTTATGCGG TAAGCTGCAA GGGCAGAGG GGAAGCTGCA</td>
</tr>
<tr>
<td></td>
<td>sequence</td>
<td>AATACGTAATA AGTTAAAAAGT</td>
</tr>
</tbody>
</table>

**S18 / 43**
Table S4. **Class II LanP proteins and their predicted secretion signal peptide sequences.**

Secretion signal peptide sequences are predicted using an online tool PrediSi.\(^\text{11}\)

<table>
<thead>
<tr>
<th>Name</th>
<th>Organism</th>
<th>Accession number</th>
<th>Signal peptide (residue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LicP</td>
<td><em>B. licheniformis</em> ATCC 14580</td>
<td>AAU42937.1</td>
<td>1-24</td>
</tr>
<tr>
<td>CylA</td>
<td><em>Enterococcus faecalis</em></td>
<td>AFJ74725.1</td>
<td>1-24</td>
</tr>
<tr>
<td>CerP</td>
<td><em>Bacillus cereus</em> Q1</td>
<td>ACM15351.1</td>
<td>1-36</td>
</tr>
<tr>
<td>CrnP</td>
<td><em>Carnobacterium maltaromaticum</em></td>
<td>AHF21241.1</td>
<td>1-30</td>
</tr>
<tr>
<td>LanP</td>
<td><em>B. licheniformis</em> 9945A</td>
<td>AGN34600.1</td>
<td>1-37</td>
</tr>
<tr>
<td>LanP</td>
<td><em>Bacillus cereus</em> FRI-35</td>
<td>AFQ13336.1</td>
<td>1-25</td>
</tr>
<tr>
<td>LanP</td>
<td><em>Kyrpidia tusciae</em> DSM 2912</td>
<td>ADG07479.1</td>
<td>1-31</td>
</tr>
<tr>
<td>LanP</td>
<td><em>Enterococcus cacaee</em> ATCC BAA-1240</td>
<td>EOL44526.1</td>
<td>1-28</td>
</tr>
<tr>
<td>LanP</td>
<td><em>Bacillus cereus</em> VPC1401</td>
<td>YP_004050051.1</td>
<td>1-31</td>
</tr>
<tr>
<td>LanP</td>
<td><em>Bacillus bombysepticus</em></td>
<td>AHX21587.1</td>
<td>1-31</td>
</tr>
<tr>
<td>LanP</td>
<td><em>Bacillus thuringiensis</em> DB27</td>
<td>CDN38711.1</td>
<td>1-36</td>
</tr>
<tr>
<td>LanP</td>
<td><em>Planomicrobium glacier</em> CHR43</td>
<td>ETP67278.1</td>
<td>1-30</td>
</tr>
<tr>
<td>LanP</td>
<td><em>Bacillus cereus</em> VD045</td>
<td>EJR29324.1</td>
<td>1-27</td>
</tr>
<tr>
<td>LanP</td>
<td><em>Bacillus cereus</em> VD156</td>
<td>EJR72593.1</td>
<td>1-27</td>
</tr>
</tbody>
</table>
Figure S1. (a) Lanthionine synthetases and proteases involved in the biosynthesis of class I and class II lanthipeptides. (b) The biosynthetic gene cluster of lichenicidin and the cleavage events employed during lichenicidin maturation.
Figure S2. SDS-PAGE image of soluble His<sub>6</sub>-LicP-25-433-S376A.
Figure S3. Investigation whether LicP cleavage is intra- or intermolecular. To differentiate whether the self-cleavage of LicP occurred intramolecularily or intermolecularly, His$_6$-LicP-25-433 (consisting of a complex of His$_6$-LicP-25-100 and LicP-101-433) was incubated with His$_6$-LicP-25-433-S376A. The reaction was monitored by SDS-PAGE to determine if wild type LicP catalyzes the proteolytic cleavage of His$_6$-LicP-25-433-S376A. When incubated separately, His$_6$-LicP-25-433 and His$_6$-LicP-25-433-S376A did not show any changes throughout the 19-hour incubation period, whereas the full length protein His$_6$-LicP-25-433-S376A was consumed gradually when incubated with His$_6$-LicP-25-433, suggesting that cleavage of LicP can take place intermolecularly. Proteins were supplied at a final concentration of 0.1 mg/mL each.
Figure S4. SDS-PAGE (a) and MALDI-TOF MS (b) analysis of His$_6$-LicP-25-433-E100A. His$_6$-LicP-25-102-E100A, calculated M: 10,096, average; observed M+H$^+$: 10,099, average. LicP-103-433, calculated M: 37,219, average; observed M+H$^+$: 37,207, average.
Figure S5. MALDI-TOF mass spectra of linear LicA2 (a) and LicM2-modified LicA2 (b). LicA2, calculated M: 8,930, average; observed M+H$^+$: 8,929, average. LicM2-modified LicA2, calculated M-12H$_2$O: 8,714, average; observed M-12H$_2$O+H$^+$: 8,713, average. Gluconoylation at the N terminus of LicA2 was introduced when expressing the peptide in *E. coli* BL21(DE3), resulting in a +178 Da peak in addition to the peak with the desired mass.\textsuperscript{11}
Figure S6. MALDI-TOF mass spectra for LicM2 modified LicA2 (a) and linear LicA2 (b) incubated with LicP. Licβ, calculated M: 3,019.4, monoisotopic; observed M+H+: 3,020.6, monoisotopic. LicA2 leader peptide, calculated M: 5,711, average; observed M+H+: 5,711, average (a), 5,713, average (b). Linear LicA2 core peptide was not observed presumably due to poor solubility and/or ionization efficiency.
Figure S7. Analysis of the time dependence of LicP activity toward modified and linear LicA2 peptides. Consumption of precursor peptide and appearance of leader peptide were monitored by both HPLC and SDS-PAGE. (a) HPLC traces: Left: Incubation of 100 μM linear LicA2 with 0.4 μM LicP. Right: Incubation of 100 μM modified LicA2 with 0.4 μM LicP. black: 0 min; red: 5 min; blue: 15 min; green: 30 min; orange: 2 h. (b) Graphs of different time points (x axis) vs. percentages of precursor peptide remaining and leader peptide formed (y axis) as calculated from peak areas in the HPLC traces: Top left: linear LicA2 remaining (circles) and leader peptide formed (squares) with 0.4 μM LicP. Top right: modified LicA2 remaining (circles) and leader peptide formed (squares) with 0.4 μM LicP. Bottom: modified LicA2 remaining with 0.4 μM (circles) and 0.1 μM LicP (squares). Absorbance was monitored at 220 nm. (c) SDS-PAGE analysis of HPLC samples with consecutive coomassie and silver staining. (d) Competitive MALDI-TOF MS assay of modified LicA2 and linear G-LicA2 peptides treated with LicP, monitoring the consumption of precursor peptides (Top) and expanded-view MALDI-TOF mass spectra of modified LicA2 and linear G-LicA2 peptides treated with or without LicP (Bottom). Modified LicA2 and linear G-LicA2 were each supplied with a final concentration of 17 μM. For the purple trace, 2.1 μM of LicP was added and the reaction was incubated at room temperature for 12 h (asterisk); for the other traces, 21 nM LicP was employed. The intensity of the highest peak observed in the region of 8,600-9,000 Da was set to 100%. No signal was observed in this region for the purple trace. Although linear and modified LicA2 were present at the same concentration, at t = 0, the modified peptide is the highest intensity peak because of higher ionization efficiency. At t = 5 min, almost all modified LicA2 has been consumed and the linear LicA2 peak is now set to 100% (the relative increase in intensity of the linear LicA2 peak does not signify that its concentration is increased). Linear LicA2 core peptide was not observed presumably due to poor solubility.
Lanes: 1: #161-0326 ladder; 2: linear LicA2; 3: linear LicA2, 5 min with 0.4 μM LicP; 4: linear LicA2, 15 min with 0.4 μM LicP; 5: linear LicA2, 30 min with 0.4 μM LicP; 6: linear LicA2, 2 h with 0.4 μM LicP; 7: modified LicA2; 8: modified LicA2, 5 min with 0.4 μM LicP; 9: modified LicA2, 15 min with 0.4 μM LicP; 10: modified LicA2, 30 min with 0.4 μM LicP; 11: modified LicA2, 5 min with 0.1 μM LicP; 12: modified LicA2, 15 min with 0.1 μM LicP; 13: modified LicA2, 30 min with 0.1 μM LicP; 14: modified LicA2, 2 h with 0.1 μM LicP; 15: #161-0326 ladder.
Figure S8. MALDI-TOF analyses of NDVNPE-ProcA1.7 (a and b) and NDVNPE-NisA (a and c) peptides and their cleaved products when incubated with LicP (d and e). NDVNPE-ProcA1.7, calculated M: 12,244, average; observed M+H+: 12,246, average. NDVNPE-NisA, calculated M: 7,557, average; observed M+H+: 7,558, average. ProcA1.7 core peptide, calculated M: 2,256.1, monoisotopic; observed M+H+: 2,257.6, monoisotopic. NDVNPE-ProcA1.7 leader peptide, calculated M: 10,004, average; observed M+H+: 10,003, average. NisA core peptide, calculated M: 3,495.6, monoisotopic; observed M+H+: 3,496.4, monoisotopic. NDVNPE-NisA leader peptide, calculated M: 4,074.9, monoisotopic; observed M+H+: 4,075.5, monoisotopic. Gluconoylation at the N terminus of NDVNPE-NisA was introduced when expressing the peptide in *E. coli* BL21(DE3), resulting in a +178 Da peak in addition to the peak with the desired mass. The reasons why some peptides are gluconoylated and others not are not known.
Figure S9. MBP-BamL protein incubated with TEV or LicP. MBP-BamL (50 µM) was incubated with LicP or TEV (final concentration 0.54 µM) at 4 °C and the reactions were quenched at different time points before analysis by SDS-PAGE. O/N: overnight.

- 97.4 kDa
- 66.2 kDa
- 45.0 kDa
- 31.0 kDa
Figure S10. MALDI-TOF mass spectra for NDVNPE-NisA peptides with various P1’ substitutions. Gluconoylation at the N terminus of NDVNPE-NisA peptides was introduced when expressing these peptides in *E. coli* BL21(DE3), resulting in a +178 Da peak in addition to the peak of the desired mass. An unidentified modification of +58 Da was installed on NDVNPE-NisA-I1K, but MALDI-TOF MS analysis suggests that the desired species is the major product.
Figure S11. MALDI-TOF mass spectra for NDVNPE-NisA peptides with various P1’ substitutions incubated with LicP. For all reactions, 0.5 mg/mL (65 µM) of NisA variants were included. For NDVNPE-NisA-I1T and NDVNPE-NisA-I1C, LicP was supplied at a final concentration of 0.01 mg/mL (210 nM) (enzyme:substrate = 310:1) and the reactions were incubated at room temperature for 20 hours. For other NisA variants, LicP was supplied at a final concentration of 0.1 mg/mL (2.1 µM) (enzyme:substrate = 31:1) and the reactions were incubated at room temperature for 30 hours.
Figure S12. The organization of LicP, including the prodomain, cleavage site, and protease domain. The large distance separating the two ends of the peptides that are formed by protease cleavage is indicated.
Figure S13. LicP assay with wild type LicA2, LicA2-E–1A, and LicA2-E–1Q.
Linear LicA2 peptides (100 μM) were incubated with 0.4 μM LicP for 30 min, 2 h or 7.5 h. The reactions were quenched with formic acid and the assay was analyzed by SDS-PAGE with consecutive coomassie and silver staining.
Figure S14. LicP assay with wild type LicA2, LicA2-E–1D, and LicA2-D–5K.
Linear LicA2 peptides (100 μM) were incubated with 0.4 μM LicP for 30 min, 2 h or 7.5 h. Then the reactions were quenched with formic acid and the assay was analyzed by SDS-PAGE with consecutive coomassie and silver staining.
Figure S15. LicP assay with wild type LicA2, LicA2-V–4F, and LicA2-D–5A.
Linear LicA2 peptides (100 μM) were incubated with 0.4 μM LicP for 30 min, 2 h or 7.5 h. The reactions were quenched with formic acid and the assay was analyzed by SDS-PAGE with consecutive coomassie and silver staining.
Figure S16. LicP assay with wild type LicA2, LicA2-V–4N, and LicA2-D–5V.
Linear LicA2 peptides (100 μM) were incubated with 0.4 μM LicP for 30 min, 2 h or 7.5 h. The reactions were quenched with formic acid and the assay was analyzed by SDS-PAGE with consecutive coomassie and silver staining.
Figure S17. LicP assay with wild type LicA2, LicA2-V–4A, and LicA2-V–4L.
Linear LicA2 peptides (100 μM) were incubated with 0.4 μM LicP for 15 min, 1 h or 2 h. The reactions were quenched with formic acid and the assay was analyzed by SDS-PAGE with consecutive coomassie and silver staining.

Figure S18. LicP assay with wild type LicA2, LicA2-P–2A, and LicA2-N–3A.
Linear LicA2 peptides (100 μM) were incubated with 0.4 μM LicP for 15 min, 1 h or 2 h. The reactions were quenched with formic acid and the assay was analyzed by SDS-PAGE with consecutive coomassie and silver staining.
Figure S19. Thirteen class II lanthipeptide biosynthetic gene clusters containing LanP genes. Substrate LanA sequences are listed under the genetic pathways and the putative LanP recognition sequences are highlighted. The predicted sites were verified for the proteins from *B. licheniformis* 9945A and *B. cereus* VD156 (see Figure S20). Clusters were annotated using the standard lanthipeptide biosynthesis nomenclature: LanM proteins catalyze the dehydrations and cyclizations, LanA peptides are lanthipeptide precursors, LanT proteins are transporters with a Cys protease domain, LanJ enzymes are dehydrogenases, LanEFGHI are immunity-conferring proteins, and LanR are regulatory proteins. The cytolysin cluster has historically been annotated differently: The substrates are CylL and CylLs, CylB is a transporter with a protease domain, and CylA is the class II LanP. Genes with unknown functions are indicated with X. The cluster for *B. cereus* VD156 is located on four different subcontigs and was manually assembled. LanA3 was chosen for expression since it was entirely on one contig unlike some of the other LanAs.
Figure S20. MALDI-TOF mass spectra of two LanA precursor peptides treated with their corresponding LanP proteases that were identified in the genomes of *B. licheniformis* 9945A (a) and *B. cereus* VD156 (b). For the dehydrated and cyclized LanA2 peptide from *B. licheniformis* 9945A, fully modified core peptide is observed after protease treatment (inset): calculated [M+Na]$^+$: 2,493.0, monoisotopic mass; observed [M+Na]$^+$: 2,493.4, monoisotopic mass; the leader peptide is also observed: calculated M: 6,478, average mass; observed [M+H]$^+$: 6,482, average mass. For the LanA3 peptide encoded by the genome of *B. cereus* VD156, the core and leader peptides were observed after protease treatment. Core peptide: calculated M: 3,382.7, monoisotopic mass; observed [M+H]$^+$: 3,381.8, monoisotopic mass; leader peptide: calculated M: 5,126.5, monoisotopic mass; observed [M+H]$^+$: 5,127.9, monoisotopic mass. The observed proteolytic products are consistent with the cleavage sites predicted in Figure S19.
References